Siponimod
http://dbpedia.org/resource/Siponimod an entity of type: Thing
Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration. In March 2019, it was approved in the United States to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
rdf:langString
rdf:langString
Siponimod
xsd:integer
49018306
xsd:integer
1090702418
rdf:langString
AA42
rdf:langString
L04
xsd:integer
29
xsd:integer
1230487
xsd:integer
2336071
xsd:integer
29315058
rdf:langString
DB12371
xsd:integer
3
xsd:integer
35
rdf:langString
as salt
xsd:integer
1
rdf:langString
D11072
rdf:langString
D11460
rdf:langString
Rx-only
rdf:langString
POM
rdf:langString
Rx-only
rdf:langString
a619027
xsd:integer
2
xsd:integer
3
xsd:integer
44599207
rdf:langString
CCC1=CCN4CCCO
xsd:integer
1
rdf:langString
KIHYPELVXPAIDH-HNSNBQBZSA-N
rdf:langString
BAF-312
rdf:langString
Mayzent
rdf:langString
RR6P8L282I
xsd:integer
275
rdf:langString
Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration. In March 2019, it was approved in the United States to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
rdf:langString
Siponimod
rdf:langString
S4
rdf:langString
Rx-only
rdf:langString
Rx-only
rdf:langString
yes
rdf:langString
Mayzent
rdf:langString
D
xsd:nonNegativeInteger
11424
rdf:langString
Mayzent
xsd:string
1230487-00-9
xsd:string
2336071
xsd:string
DB12371
xsd:string
RR6P8L282I
xsd:string
D11072
D11460
xsd:string
a619027
xsd:string
44599207